News | May 29, 2023
Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
The company had responded to the agency and carried out the required corrective actions.
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
Subscribe To Our Newsletter & Stay Updated
